ATTO

Attovia Therapeutics, Inc.

Latest Form 4:Purchase$1.8MbyWALSH COLIN (Director) · filed Aug 14, 2026

Attovia Therapeutics, Inc. (ATTO) has 7 SEC Form 4 filings (69 transaction rows) in the rolling window, disclosed by 6 distinct insiders. Most recent filing: Aug 14, 2026.

The most active filer is Director WALSH COLIN with 3 filings. Insiders have net bought $47.9M over the trailing 6 months. The largest single insider purchase in this window was $10.2M by 10% Owner Redmile Group, LLC on Aug 6, 2026.

  • Industry:Biotechnology
  • HQ:San Carlos, CA, US
  • IPO:2026-08-05

Insider Buying

$52.4M

reported purchases (SEC code P)

Insider Selling

$4.5M

reported sales (SEC code S)

Unique Insiders

6

in the rolling window

Source
WALSH COLINFirst filing
Purchase$1.8MAug 14SEC ↗
WALSH COLINFirst filing
Sale$2.2MAug 14SEC ↗
WALSH COLINFirst filing
Purchase$8.5MAug 14SEC ↗
Purchase$1.8MAug 14SEC ↗
Sale$2.2MAug 14SEC ↗
Purchase$8.5MAug 14SEC ↗
Purchase$6.5MAug 10SEC ↗
Redmile Group, LLCFirst in 4 months
Purchase$10.2MAug 8SEC ↗
SanofiFirst filing
Purchase$5.1MAug 7SEC ↗
Purchase$10.0MAug 6SEC ↗

Related companies

Attovia Therapeutics, Inc. is in the Healthcare sector.